Subacromial Injection of Allogeneic Platelet Rich Plasma (PRP) for Shoulder Impingement Syndrome
Primary Purpose
Shoulder Impingement Syndrome
Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Steroid injection into the subacromial space
Allogeneic PRP injection into the subacromial space
Sponsored by
About this trial
This is an interventional treatment trial for Shoulder Impingement Syndrome
Eligibility Criteria
Inclusion Criteria:
- Male or female 18 years of age and older
- Patients who have unilateral shoulder pain.
- Patients who have had pain at least for 3 months
To be included in the study- participants are required to have a & b.(mentioned below)
Pain with one of the two tests
- Neer's sign: passive overpressure at full shoulder flexion with the scapula fixed
- Hawkins test: passive internal rotation at 90 degree of shoulder flexion in the scapular plane and in progressive degree of horizontal adduction
Pain with one of the two tests
- Painful arc: active shoulder abduction
- Jobe's test: The examiner passively elevates the patient's shoulder to 90 degrees of abduction with internal rotation. The examiner then applies a downward pressure against the arm
Exclusion Criteria:
- Patients who received any drug by subacromial injection for treatment within 3 months prior to this enrollment.
- Patients who have a history of shoulder trauma including dislocation- subluxation- and fracture- breast cancer- or surgery around shoulder- neck and upper back
- Patients who have a isolated acromioclavicular joint pathology
- Patients who have a full-thickness rotator cuff tear (evidenced by MR or ultrasonography)
- Patients with symptomatic cervical spine disorders
- Patients who have a History of allergic adverse reactions to corticosteroid
- Patients are unable to give informed consent to participate in the study
- Patients are unable to come into the clinic for regular follow-up
- Patients with adhesive capsulitis- acromioclavicular arthropathy- polyarthritis- infectious arthritis- rheumatoid arthritis or diagnosed fibromyalgia
- Patients with concurrent bilateral shoulder pain
- Patients with neurological deficit
- Patients who have severely abnormal radiological findings including malignancy, severe osteoarthritis of the glenohumeral joint, severe skeletal abnormalities decreasing the subacromial space and etc.
- Presence of shoulder pain with limitation of both active and passive movements of the glenohumeral joint of 25% in at least 2 directions (abduction, flexion, external rotation, internal rotation), as compared with the contralateral shoulder or with normal values
- Patients with Diabetes mellitus
- Patients taking anticoagulants
- Pregnant women or lactating mothers
- Patients who are difficulty participating in data collection due to communication problem and serious mental illness
- Patients with serious condition which can affect this study such as severe cardiovascular diseases- renal diseases- liver diseases- endocrine diseases- and cancers
Sites / Locations
- Joint & Spine Center, SMG-SNU Boramae Medical Center, Department of Orthopedic Surgery, Seoul National University College of Medicine
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Steroid group
PRP group
Arm Description
Triamcinolone injection group
Allogeneic PRP injection group
Outcomes
Primary Outcome Measures
Safety determined with symptoms & signs of infection and immune response and adverse events evaluated with NCI-CTCAE v3.0
Presence of general symptoms or signs associated with infection and immune response, such as rash, pruritus, fever, chills, urticaria, or dyspnea.
Injection sites were examined to identify erythema, swelling, or abnormal discharge.
Adverse events were categorised with use of the National Cancer Institute Common Terminology Criteria for Adverse Events scale, version 3.0.
Constant-Murley score
The Constant-Murley score (CMS) is a 100-points scale composed of parameters defining the level of pain and the ability of performing daily activities.
Secondary Outcome Measures
Full Information
NCT ID
NCT02019537
First Posted
December 18, 2013
Last Updated
September 16, 2020
Sponsor
Seoul National University Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02019537
Brief Title
Subacromial Injection of Allogeneic Platelet Rich Plasma (PRP) for Shoulder Impingement Syndrome
Official Title
Allogeneic Platelet-Rich Plasma Versus Corticosteroid Injection for the Treatment of Rotator Cuff Disease: A Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
September 2020
Overall Recruitment Status
Completed
Study Start Date
February 2014 (undefined)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
July 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to investigate the efficacy of allogeneic PRP in patients with subacromial impingement disease
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Shoulder Impingement Syndrome
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Steroid group
Arm Type
Active Comparator
Arm Description
Triamcinolone injection group
Arm Title
PRP group
Arm Type
Experimental
Arm Description
Allogeneic PRP injection group
Intervention Type
Procedure
Intervention Name(s)
Steroid injection into the subacromial space
Intervention Description
Group: Steroid
Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)
The number of injections : only once during the study period
Injection site : subacromial space
Material : 25-gauze spinal needle
Subacromial injections were performed using ultrasonographic guidance.
Intervention Type
Procedure
Intervention Name(s)
Allogeneic PRP injection into the subacromial space
Intervention Description
Group: Allogeneic PRP
Total volume of injection drugs: 4ml
The number of injections : only once during the study period
Injection site : subacromial space
Material : 25-gauze spinal needle
Subacromial injections were performed using ultrasonographic guidance.
Primary Outcome Measure Information:
Title
Safety determined with symptoms & signs of infection and immune response and adverse events evaluated with NCI-CTCAE v3.0
Description
Presence of general symptoms or signs associated with infection and immune response, such as rash, pruritus, fever, chills, urticaria, or dyspnea.
Injection sites were examined to identify erythema, swelling, or abnormal discharge.
Adverse events were categorised with use of the National Cancer Institute Common Terminology Criteria for Adverse Events scale, version 3.0.
Time Frame
Postinjection 1month
Title
Constant-Murley score
Description
The Constant-Murley score (CMS) is a 100-points scale composed of parameters defining the level of pain and the ability of performing daily activities.
Time Frame
Postinjection 1month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female 18 years of age and older
Patients who have unilateral shoulder pain.
Patients who have had pain at least for 3 months
To be included in the study- participants are required to have a & b.(mentioned below)
Pain with one of the two tests
Neer's sign: passive overpressure at full shoulder flexion with the scapula fixed
Hawkins test: passive internal rotation at 90 degree of shoulder flexion in the scapular plane and in progressive degree of horizontal adduction
Pain with one of the two tests
Painful arc: active shoulder abduction
Jobe's test: The examiner passively elevates the patient's shoulder to 90 degrees of abduction with internal rotation. The examiner then applies a downward pressure against the arm
Exclusion Criteria:
Patients who received any drug by subacromial injection for treatment within 3 months prior to this enrollment.
Patients who have a history of shoulder trauma including dislocation- subluxation- and fracture- breast cancer- or surgery around shoulder- neck and upper back
Patients who have a isolated acromioclavicular joint pathology
Patients who have a full-thickness rotator cuff tear (evidenced by MR or ultrasonography)
Patients with symptomatic cervical spine disorders
Patients who have a History of allergic adverse reactions to corticosteroid
Patients are unable to give informed consent to participate in the study
Patients are unable to come into the clinic for regular follow-up
Patients with adhesive capsulitis- acromioclavicular arthropathy- polyarthritis- infectious arthritis- rheumatoid arthritis or diagnosed fibromyalgia
Patients with concurrent bilateral shoulder pain
Patients with neurological deficit
Patients who have severely abnormal radiological findings including malignancy, severe osteoarthritis of the glenohumeral joint, severe skeletal abnormalities decreasing the subacromial space and etc.
Presence of shoulder pain with limitation of both active and passive movements of the glenohumeral joint of 25% in at least 2 directions (abduction, flexion, external rotation, internal rotation), as compared with the contralateral shoulder or with normal values
Patients with Diabetes mellitus
Patients taking anticoagulants
Pregnant women or lactating mothers
Patients who are difficulty participating in data collection due to communication problem and serious mental illness
Patients with serious condition which can affect this study such as severe cardiovascular diseases- renal diseases- liver diseases- endocrine diseases- and cancers
Facility Information:
Facility Name
Joint & Spine Center, SMG-SNU Boramae Medical Center, Department of Orthopedic Surgery, Seoul National University College of Medicine
City
Seoul
ZIP/Postal Code
156-707
Country
Korea, Republic of
12. IPD Sharing Statement
Learn more about this trial
Subacromial Injection of Allogeneic Platelet Rich Plasma (PRP) for Shoulder Impingement Syndrome
We'll reach out to this number within 24 hrs